Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714932 | 0.88 | CYP2C9 (0.40) | CYP2C9HDAC6ALDH1A1MEN1TSHR | |
| SCHEMBL2807725 | 0.82 | CYP2C9 (0.55) | CYP2C9PTGDR2HDAC6MEN1KMT2A | |
| SCHEMBL3456353 | 0.82 | PTGDR2 (0.39) | PTGDR2HDAC6CXCR2MAOBCMA1 | |
| SCHEMBL4713891 | 0.80 | CYP2C9 (0.44) | CYP2C9PTGDR2HDAC6CXCR2ALDH1A1 | |
| SCHEMBL2803782 | 0.80 | CYP2C9 (0.54) | CYP2C9PTGDR2HDAC6ALDH1A1KDM4E | |
| SCHEMBL4715057 | 0.80 | CYP2C9 (0.41) | CYP2C9PTGDR2HDAC6MEN1KMT2A | |
| SCHEMBL4716936 | 0.79 | PTGDR2 (0.48) | CYP2C9PTGDR2 | |
| SCHEMBL4761013 | 0.78 | PTGDR2 (0.52) | CYP2C9PTGDR2 | |
| SCHEMBL4713097 | 0.78 | CYP2C9 (0.43) | CYP2C9PTGDR2CXCR2APEX1 | |
| SCHEMBL14602777 | 0.78 | CYP2C9 (0.43) | CYP2C9PTGDR2HDAC6CXCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| US-20040058941-A1 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058941-A1 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | TYMP, LPL, PLAT | CYP2C9 1906/4885PTGDR2 151/4885HDAC6 4125/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | CYP2C9 2137/4885PTGDR2 113/4885HDAC6 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.